Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness
Conditions
Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands
Contact: Study coordinator (J. Tol)Amsterdam Universitair Medische Centra, Amsterdam, Netherlands
Contact: Study coordinator (J.M. Tromp)Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, Netherlands
Contact: Study coordinator (Frans Opdam, MD, PharmD, PhD)Amphia Ziekenhuis, Breda, Netherlands
Contact: Study coordinator (J. Bakker)Universitair Medisch Centrum Groningen, Groningen, Netherlands
Contact: Study coordinator (A.K.L. Reyners)Leiden University Medical Center, Leiden, Netherlands
Contact: Study coordinator (J.R. Kroep)Maastricht UMC, Maastricht, Netherlands
Contact: Study coordinator (R.I. Lalisang)Radboudumc, Nijmegen, Netherlands
Contact: Study coordinator (Nielka van Erp, prof. PharmD PhD)ErasmusMC, Rotterdam, Netherlands
Contact: Study coordinator (Ron H.J. Mathijssen, prof. MD, PhD)Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
Contact: Study coordinator (I.O. Baas)
Study leads
Nielka van Erp, prof. PharmD PhD
Principal Investigator
Radboud University Medical Center